Company

Aerie Pharmaceuticals, Inc.

Headquarters: Durham, NC, United States

Founded: 1 January 2005

Employees: 376

CEO: Mr. Raj Kannan

NASDAQ: AERI +1.40%

Market Cap

$753.6 Million

USD as of Nov. 1, 2022

Market Cap History

Aerie Pharmaceuticals, Inc. market capitalization over time

Evolution of Aerie Pharmaceuticals, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Aerie Pharmaceuticals, Inc.

Detailed Description

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Top 1-year algo backtest: +284.14%

$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Aerie Pharmaceuticals, Inc. has the following listings and related stock indices.


Stock: NASDAQ: AERI wb_incandescent

Stock: FSX: 0P0 wb_incandescent

Key People

David  L.  Epstein,  M. D. Casey  C.  Kopczynski,  Ph. D (founders)

Details

Headquarters:

4301 Emperor Boulevard

Suite 400

Durham, NC 27703

United States

Phone: 919 237 5300